Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Ulla Feldt-Rasmussen’s scientific footprint (per the provided OpenAlex extracts) is dominated by **endocrinology/thyroid–pituitary epidemiology and clinical research**, including work relevant to **central hypothyroidism diagnostics** using TRH stimulation testing (). Overall, the evidence quality of any *specific claim* depends strongly on study design (cohort vs cross-sectional vs case-based), and the diagnostic usefulness of older dynamic tests should be interpreted in light of assay sensitivity and evolving guidelines (see caution notes below for uncertainty and heterogeneity).


     Long Explanation


    Author Review: Ulla Feldt-Rasmussen

    Scope used here: evidence explicitly present in your provided extracts (one detailed TRH stimulation study with numeric results + several high-cited works with DOIs). Skeptical rule: I separate what is directly supported by the study’s own data from what is inferred (e.g., clinical practice implications).

    1) What the provided raw-data study shows (TRH stimulation test)

    The study directly compares TRH-induced TSH dynamics in people with pituitary pathology vs controls to judge diagnostic add-on value for central hypothyroidism. The key result is that TSH timepoints did not significantly differ between groups and “pathological” TRH responses were not frequent enough to make TRH testing strongly informative beyond thyroid hormone status.

    Figure A — Median TSH trajectories (patients vs controls)

    Values are the provided medians at 0/20/60 min from the extracted study summary.

    Figure B — “Pathological response” proportion

    Pathological response frequency: 9/35 patients vs 2/26 controls.

    2) Scientific strength (what looks solid vs what’s uncertain)

    Supported by provided data
    • Direct empirical test of diagnostic add-on value: the study explicitly asks whether TRH stimulation distinguishes thyroid status patterns in pituitary pathology, rather than assuming it does.
    • Uses dynamic testing but finds limited separation: despite TRH, median trajectories and “pathological” rates are not strongly different.
    Critical uncertainties / likely failure modes
    • Small sample size & heterogeneity (multiple pituitary diagnoses; only 35 patients with pituitary pathology). This can dilute effect sizes and weaken subgroup discrimination.
    • Timing/measurement window: sampling at 0/20/60 min may miss discriminating kinetics outside that range.
    • Immunoassay sensitivity and era effects: older TSH/free T4 assay performance can change classification of “inappropriately normal/low” TSH and alter diagnostic conclusions; the study’s practical relevance should be re-evaluated with modern ultra-sensitive assays.
    • Confounding by treatment: provided extraction mentions exclusions for thyroid hormone replacement and other thyroid conditions, but residual confounding is still possible if clinical thyroid management differed.
    Inference boundary: The conclusion “TRH testing offers limited additional diagnostic value” is directly aligned with the reported lack of group separation at key timepoints and low frequency of pathological responses. Yet, whether TRH stimulation is obsolete clinically depends on how modern assays and current diagnostic algorithms define central hypothyroidism.

    3) Broader research footprint (from provided high-cited DOI list)

    Your provided OpenAlex-derived list suggests major themes: endocrinology (Cushing’s syndrome incidence/prognosis; thyroid effects of endocrine disruptors; thyroid function & pregnancy outcomes) and rare disease genetics/clinical chaperone therapy discussions (Fabry disease).
    • Population-based Cushing’s incidence & late prognosis is represented by a highly cited work in JCEM.
    • Thyroid and environmental endocrine disruptors appears via a review in Molecular and Cellular Endocrinology.
    • Pregnancy/thyroid autoimmunity and preterm birth is represented by a JAMA report.
    • Clinical guideline/consensus-type work is represented by an ERT recommendations document in Orphanet Journal of Rare Diseases.

    4) Citation metrics (from provided extracts; interpret carefully)

    Per your supplied OpenAlex extracts: Ulla Feldt-Rasmussen has (for the top match) 862 works_count, 23391 cited_by_count, and h_index 76; the provided “Author Citation Information” block also lists a smaller set of 2 papers with low citation totals and an h-index of 1. These disagreements indicate that author name disambiguation and database matching can materially change metric interpretation.
    Epistemic humility: Without the full list of publications used to compute “total citations / paper count,” any metric-based ranking should be treated as rough.

    5) Overall scientific strength judgment (based on what we can verify from provided material)

    • Strength: The provided TRH study is a concrete diagnostic evaluation using human clinical measurements and explicitly reports limited added value of dynamic testing.
    • Limitation: For the broader body of work, your prompt provides only bibliographic metadata and a few DOI-level snippets. Without the full study methods/results, I cannot rigorously audit effect sizes, biases, or reproducibility for each publication beyond the explicitly extracted TRH paper.
    • Blind spot: Diagnostic test usefulness is highly dependent on assay technology, reference ranges, and current definitions; older dynamic testing conclusions may not transfer 1:1 to modern practice.
    Most evidence-supported claim from provided raw data:
    TRH stimulation test performance shows limited separation between pituitary pathology patients and controls, with modest “pathological response” frequency, making TRH limited as add-on beyond thyroid hormone measurements for central hypothyroidism diagnosis in that dataset.
    Confidence level:
    Moderate for the TRH paper’s internal conclusion; Lower for extrapolation to today’s assays/practice.


    Feedback:    

    Updated: April 13, 2026

     Analysis Wizard



    Not applicable: the request is an author scientific critique using provided numeric study extracts, not a bioinformatics analysis task.



     Hypothesis Graveyard


    “TRH stimulation reliably identifies central hypothyroidism across all pituitary disorders.” This is weakened by the provided study showing non-significant separation at key timepoints and low pathological response rates.


    “TRH testing is interchangeable with baseline free T4/TSH algorithms.” The provided evidence suggests TRH adds limited value beyond thyroid hormone patterns, implying non-interchangeability.

     Science Art


    Author Review: Ulla Feldt-Rasmussen Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending